Work

More or Less? Impact of Dose Number on Outcomes of Patients with Acute Lymphoblastic Leukemia Treated with Inotuzumab Ozogamicin

Year: 2019

Type: article

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/j.clml.2019.07.034

Authors: David Marks, Daniel DeAngelo, Elias Jabbour, Anjali Advani, Susan O’Brien, Tao Wang, Alexander Neuhof, Erik Vandendries, Hagop Kantarjian, Wendy Stock, Matthias Stelljes, Ryan Cassaday

Institutions: Dana-Farber Cancer Institute, The University of Texas MD Anderson Cancer Center, Cleveland Clinic, University of California, Irvine, UC Irvine Chao Family Comprehensive Cancer Center, Pfizer (United States), Pfizer (Germany), University of Chicago, University Hospital Münster, University of Washington, Fred Hutch Cancer Center

Language: English

Topic: Acute Lymphoblastic Leukemia research

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2971026936

FWCI: 0.224

Cites:

Cited by: 1

Related to: 10